Clinical trials: Delivery Systems
Encephalopathy, Birth Defect
Clinical Utility of Pediatric Whole Exome Sequencing
The investigator aims to examine the clinical utility of WES, including assessment of a variety of clinical outcomes in undiagnosed pediatric cases.
- Conditions
- Encephalopathy, Birth Defect, Intellectual Disability, Multiple Congenital Anomaly
- Trial name
- NCT03525431
- Testing
- Whole Exome Sequencing
- Where
- 4 sites in United States
- Volunteers
- 529 people
- Sponsor
- University of California, San Francisco
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - Combo INI+EMPA Trial
The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2…
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05081219
- Testing
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Asthma
Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg
This is a 16 week multicentre, multinational, randomised, double-blind, double-dummy, placebo-controlled, parallel group study to evaluate the long-term efficacy and safety of tiotropium compared to salmeterol in moderate…
- Trial name
- NCT00350207
- Testing
- Tiotropium bromide, Salmeterol xinafoate
- Where
- 109 sites in Austria, Belgium and 12 more
- Volunteers
- 388 people
- Sponsor
- Boehringer Ingelheim
Erectile Dysfunction
Caverject User Study
The purpose of this study is to demonstrate the usability of the system.
- Trial name
- NCT01008605
- Testing
- delivery system
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma
This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.
- Trial name
- NCT00545272
- Testing
- indacaterol, formoterol, short acting β2-agonist
- Where
- 60 sites in Belgium, Czechia and 8 more
- Volunteers
- 392 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Treated With Insulin
Control-IQ Technology in Individuals With Type 2 Diabetes
A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
- Trial name
- 2IQ (NCT05111301)
- Testing
- Control-IQ technology 1.5
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tandem Diabetes Care, Inc.
HIV Infections, Drug Use
INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit
The purpose of this study is to determine the efficacy of using a mobile health delivery unit ("mobile unit") to deliver "one stop" integrated health services - particularly medication for opioid use disorder (MOUD) and…
- Conditions
- HIV Infections, Drug Use, Opioid Use, Opioid-use Disorder
- Trial name
- INTEGRA (NCT04804072)
- Testing
- Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD), HIV testing, HIV treatment for participants living with HIV not already in care
- Where
- 5 sites in United States
- Volunteers
- 447 people
- Sponsor
- HIV Prevention Trials Network
Iliac Artery Occlusive Disease
A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System
To determine the safety and effectiveness of the LUMINEXX stent for the proposed indication of treatment of common and/or external iliac artery occlusive disease
- Trial name
- Luminexx (NCT00561457)
- Testing
- Bard Luminexx Iliac Stent and Delivery System
- Volunteers
- 134 people
- Sponsor
- C. R. Bard
Multiple Sclerosis
Teleconference Fatigue Management for People With Multiple Sclerosis
Approximately 60% of individuals with multiple sclerosis (MS) describe fatigue as their most disabling symptom. Energy conservation education involves teaching people with MS different strategies to manage fatigue and reduce its…
- Trial name
- NCT00591721
- Testing
- Energy conservation education
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Illinois Chicago
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
This study is conducted in Europe. The aim of this study is to compare the easiness of use of Norditropin NordiFlex® device to the device previously used by patients or parents.
- Conditions
- Growth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem, Small for Gestational Age
- Trial name
- NCT01245374
- Testing
- Norditropin NordiFlex®
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Novo Nordisk A/S
Hepatitis C
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with…
- Trial name
- COPE-HCV (NCT00919633)
- Testing
- interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Cystic Fibrosis
Effects of Sildenafil on CFTR-dependent Ion Transport Activity
Dehydrated airway surfaces resulting from sodium hyperabsorption and lack of chloride secretion are critical to the pathology that leads to the morbidity and mortality from Cystic Fibrosis (CF) lung disease.
- Trial name
- NCT01132482
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Jewish Health
Anaplastic Astrocytoma, Glioblastoma
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed recurrent or refractory anaplastic astrocytoma…
- Trial name
- SAPPHIRE (NCT00761280)
- Testing
- trabedersen, temozolomide, Drug delivery system for administration of AP 12009
- Where
- 68 sites in United States, Argentina and 14 more
- Volunteers
- 27 people
- Sponsor
- Isarna Therapeutics GmbH
Contraception
Early Postpartum Intrauterine Device (IUD) Placement
Women who have just given birth are at high risk for rapid repeat pregnancy, which can lead to negative consequences during the subsequent pregnancy.
- Trial name
- NCT01594476
- Testing
- Levonorgestrel IUS
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Gulf War Illness, Insomnia
Cognitive Behavioral Therapy for Insomnia for Gulf War Illness
Sleep disturbance is a common complaint of Veterans with Gulf War Illness (GWI). Because there is clinical evidence that sleep quality influences pain, fatigue, mood, cognition, and daily functioning, this study will investigate…
- Trial name
- CBTi GWI (NCT02782780)
- Testing
- Cognitive Behavioral Therapy for Insomnia (CBTi)
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- VA Office of Research and Development
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe…
- Trial name
- NCT00313846
- Testing
- Buprenorphine transdermal patch
- Where
- 44 sites in United States
- Volunteers
- 529 people
- Sponsor
- Purdue Pharma LP
Heat Effect
Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products
This research study is intended to determine the effect of heat and occlusion on oxybutynin products.
- Trial name
- NCT03205605
- Testing
- oxybutynin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hepatocellular Carcinoma
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Open-label study to evaluate the safety and tolerability of Sorafenib dose ramp-up (starting at a lower dose and then gradually increasing the dose) versus standard Sorafenib dosing in subjects with unresectable and/or metastatic…
- Trial name
- NCT01203787
- Testing
- Sorafenib Standard Dosing Regimen, Sorafenib Ramp-Up Regimen
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Florida
Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with B cell lymphomas or leukemias that involves taking white blood cells from the patient, growing them…
- Conditions
- Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, Mantle Cell
- Trial name
- NCT00924326
- Testing
- Fludarabine, Cyclophosphamide, Anti-cluster of differentiation 19 (CD19)-CAR PBL
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Pseudocyst(s)
AXIOS Stent With Electrocautery Enhanced Delivery System
The purpose of this study is to demonstrate the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic transenteric drainage of pancreatic pseudocysts.
- Trial name
- NCT02146352
- Testing
- AXIOS Stent with Electrocautery Enhanced Delivery System
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Xlumena, Inc.